Muhammad Torequl Islam*
Department of Pharmacy, Life Science Faculty, Bangabandhu Sheikh Mujibur Rahman Science and Technology University, Gopalganj-8100, Bangladesh
*Corresponding Author: Muhammad Torequl Islam, Department of Pharmacy, Life Science Faculty, Bangabandhu Sheikh Mujibur Rahman Science and Technology University, Gopalganj-8100, Bangladesh.
Received: September 09, 2020; Published: November 25, 2020
The nuclear factor-erythroid 2 p45-related factor 2 (Nrf2) regulates many important genes that encode of our body antioxidant systems and display diverse and important physiological functions. Loss of Nrf2 is associated with an upregulated expression of angiotensin converting enzyme 2 receptor (ACE2R) in experimental animals. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) use ACE2R for the entry in human lung epithelial and enteric cells through binding with its spike glycoprotein (S). ACE2 upregulation is associated with many diseases, including liver injury, inflammation and insulin resistance, myocardial dysfunction, acute decompensated heart failure, and type 2 diabetes. However, deletion or loss of its activity is associated with atherosclerotic renal injury and kidney diseases, heart failure, and pulmonary arterial hypertension. Therefore, targeting Nrf2 alone or Nrf2-ACE2 modulators might be helpful to manage these types of patients with SARS-CoV-2 infection. Adequate pre-clinical and clinical research is necessary to establish this concepts.
Keywords: ACE2; Nrf2; SARS-CoV-2; Covid-19
Citation: Muhammad Torequl Islam. “Nrf2-ACE2R Pathway to Halt the Entrance of SARS-CoV-2 in Human: A New Strategy in Targeted Therapy". Acta Scientific Otolaryngology 2.12 (2020): 32-37.
Copyright: © 2020 Muhammad Torequl Islam. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.